Moore KN et al. |
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. |
2018 |
Gynecol. Oncol. |
pmid:30093227
|
Wang L et al. |
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. |
2018 |
Cancer Sci. |
pmid:30076657
|
Jin W et al. |
LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. |
2018 |
Bioanalysis |
pmid:29863890
|
Menchon G et al. |
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. |
2018 |
Nat Commun |
pmid:29844393
|
Johnson TA and Singla DK |
Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. |
2018 |
Can. J. Physiol. Pharmacol. |
pmid:29842793
|
Barok M et al. |
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. |
2018 |
BMC Cancer |
pmid:29720111
|
Sakai H et al. |
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
2018 |
Breast Cancer |
pmid:29700710
|
Escrivá-de-Romanà S et al. |
HER2-positive breast cancer: Current and new therapeutic strategies. |
2018 |
Breast |
pmid:29631097
|
Moore KN et al. |
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29424243
|
Ricciardi GRR et al. |
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. |
2018 |
BMC Cancer |
pmid:29370839
|